To Assess the Effectiveness and Safety of Catheter-based Focal Intracranial Hypothermia Combined with Endovascular Reperfusion Therapy for Patients with Acute Anterior Circulation Large Artery Occlusion

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorGuangdong Second Provincial General Hospital

About this trial

A multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial to assess the effectiveness and safety of catheter-based focal intracranial hypothermia combined with endovascular reperfusion therapy for patients with acute anterior circulation large artery occlusion.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 and ≤85 years old.

Symptoms of sudden focal or general neurological impairment.

There may be a causal relationship between vascular occlusion and nerve function defect.

Time from symptom onset to randomization ≤24h.

Disqualifiers

Pre stroke mRS>1 score.

There are acute infarcts in both cerebral hemispheres and/or anterior and posterior circulation.

NIHSS≤6 points.

Cerebral hemorrhage/subarachnoid hemorrhage was confirmed by CT or MRI. 5.The presence of active bleeding, severe anemia, coagulation dysfunction, or an uncorrected bleeding tendency (Presence of at least one of the following laboratory tests: hemoglobin < 10g /dl, platelet count < 100,000 /μl, uncorrected INR>1.5, PT> 1 minute above the upper limit of normal, or heparin-related thrombocytopenia).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Mechanical thrombectomy

    Procedure/Surgery

    Mechanical thrombectomy

  • 4°C saline infusion

    Drug

    Patients received a total of 350 ml of 4°C saline infusion in addition to mechanical thrombectomy (MT).

  • Normothermic saline infusion

    Drug

    Patients received a total of 350 ml of roomtemperature saline infusion in addition to mechanical thrombectomy (MT).

Treatment groups

262 Participants
are divided into 2 treatment groups
Group A: Mechanical thrombectomy combined with intra-arterial selective cooling infusion (hypothermia) groupExperimental treatment 2 interventions
Group B: Mechanical thrombectomy combined with normothermic saline infusion (normothermia) groupActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Proportion of patients with modified Rankin Score 0-2 at 90 days.

The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

Time frame
90 days after procedure

Secondary outcomes

1

Proportion of patients with modified Rankin Score 0-1 at 90 days

The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

Time frame
90 days after procedure
2

Successful reperfusion rate

Successful reperfusion was indicated by modified Thrombolysis in Cerebral Infarction (mTICI) grade 2b or 3.

Time frame
At the end of the operation
3

Cerebral infarction volume was measured by CT or magnetic resonance DWI 72 hours to 7 days after operation

Cerebral infarction volume was measured by CT or DWI 72 hours to 7 days after operation.

Time frame
72 hours to 7 days after procedure
4

Incidence of early neurological deterioration

Early neurological deterioration was defined as an increase of 4 or more points on the NIHSS within 24 hours that was not attributable to intracerebral hemorrhage.

Time frame
Within 24 hours after procedure

Other outcomes

1

Rate of symptomatic intracranial hemorrhage within 72 hours (Heidelberg Bleeding Classification)

Intracranial hemorrhage (ICH) was assessed with the Heidelberg Bleeding Classification within 72 hours of endovascular treatment. Intracranial hemorrhage was classified as hemorrhagic infarction or parenchymal hematoma. The sICH was defined as ICH associated with a worsening of 4 or more points on the NIHSS or resulting in death, and cerebral herniation, which were not present at baseline.

Time frame
Within 72 hours after procedure
2

Rate of coagulation disorders

Rate of coagulation disorders within 7 days

Time frame
7 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.